Novartis adds to its cardio pipeline with $1.65B Ionis pact
Novartis is making a big bet on two of Ionis’ cardio drugs.
The pharma giant $NVS is handing over $225 million in near-term payments, split between fees, an upfront and an equity stake, and promising $1.13 billion more in development and commercialization milestones for a worldwide option and collaboration pact on AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx — handled by Ionis’ subsidiary Akcea.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
